{"id":"https://openalex.org/W33642896","doi":"https://doi.org/10.1182/blood.v122.21.4120.4120","title":"T-Cell Dysfunction In CLL Is Mediated Not Only By PD-1/PD-L1 But Also By PD-1/PD-L2 Interactions - Partial Functionality Is Maintained In PD-1 Defined CD8 Subsets and This Can Be Further Promoted By Ibrutinib Treatment","display_name":"T-Cell Dysfunction In CLL Is Mediated Not Only By PD-1/PD-L1 But Also By PD-1/PD-L2 Interactions - Partial Functionality Is Maintained In PD-1 Defined CD8 Subsets and This Can Be Further Promoted By Ibrutinib Treatment","publication_year":2013,"publication_date":"2013-11-15","ids":{"openalex":"https://openalex.org/W33642896","doi":"https://doi.org/10.1182/blood.v122.21.4120.4120","mag":"33642896"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v122.21.4120.4120","doi":"https://doi.org/10.1182/blood.v122.21.4120.4120","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.4120.4120","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5107969739","display_name":"Fabienne McClanahan","orcid":"https://orcid.org/0000-0001-5521-3271","observed_orcids":["https://orcid.org/0000-0001-5521-3271"]},"institutions":[{"id":"https://openalex.org/I17937529","display_name":"German Cancer Research Center","ror":"https://ror.org/04cdgtt98","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I17937529"]}],"countries":["DE"],"is_corresponding":true,"raw_author_name":"Fabienne McClanahan","raw_affiliation_strings":["German Cancer Research Center (DKFZ), Heidelberg, Germany,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"German Cancer Research Center (DKFZ), Heidelberg, Germany,","institution_ids":["https://openalex.org/I17937529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028402374","display_name":"Shaun Miller","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405264518","display_name":"Barts Cancer Institute","ror":"https://ror.org/0266wrt04","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079","https://openalex.org/I4405264518"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Shaun Miller","raw_affiliation_strings":["Centre for Haemato-Oncology, Barts Cancer Institute, London, United Kingdom,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre for Haemato-Oncology, Barts Cancer Institute, London, United Kingdom,","institution_ids":["https://openalex.org/I4405264518"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001047632","display_name":"John Charles Riches","orcid":"https://orcid.org/0000-0002-3425-7686","observed_orcids":["https://orcid.org/0000-0002-3425-7686"]},"institutions":[{"id":"https://openalex.org/I4405264518","display_name":"Barts Cancer Institute","ror":"https://ror.org/0266wrt04","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079","https://openalex.org/I4405264518"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"John C. Riches","raw_affiliation_strings":["Centre for Haemato-Oncology, Barts Cancer Institute, London, United Kingdom,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre for Haemato-Oncology, Barts Cancer Institute, London, United Kingdom,","institution_ids":["https://openalex.org/I4405264518"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026718910","display_name":"Essam Ahmed Ghazaly","orcid":"https://orcid.org/0000-0003-4368-8565","observed_orcids":["https://orcid.org/0000-0003-4368-8565"]},"institutions":[{"id":"https://openalex.org/I4405264518","display_name":"Barts Cancer Institute","ror":"https://ror.org/0266wrt04","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079","https://openalex.org/I4405264518"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Essam Ghazaly","raw_affiliation_strings":["Centre for Haemato-Oncology, Barts Cancer Institute, London, United Kingdom,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre for Haemato-Oncology, Barts Cancer Institute, London, United Kingdom,","institution_ids":["https://openalex.org/I4405264518"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112467392","display_name":"William P. Day","orcid":"https://orcid.org/0009-0002-4485-2611","observed_orcids":["https://orcid.org/0009-0002-4485-2611"]},"institutions":[{"id":"https://openalex.org/I4405264518","display_name":"Barts Cancer Institute","ror":"https://ror.org/0266wrt04","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079","https://openalex.org/I4405264518"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"William P. Day","raw_affiliation_strings":["Centre for Haemato-Oncology, Barts Cancer Institute, London, United Kingdom,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre for Haemato-Oncology, Barts Cancer Institute, London, United Kingdom,","institution_ids":["https://openalex.org/I4405264518"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040118446","display_name":"Melania Capasso","orcid":"https://orcid.org/0000-0001-8659-9867","observed_orcids":["https://orcid.org/0000-0001-8659-9867"]},"institutions":[{"id":"https://openalex.org/I4405264518","display_name":"Barts Cancer Institute","ror":"https://ror.org/0266wrt04","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079","https://openalex.org/I4405264518"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Melania Capasso","raw_affiliation_strings":["Center for Cancer and Inflammation, Barts Cancer Institute, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Cancer and Inflammation, Barts Cancer Institute, London, United Kingdom","institution_ids":["https://openalex.org/I4405264518"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5067154165","display_name":"John G. Gribben","orcid":"https://orcid.org/0000-0002-8505-7430","observed_orcids":["https://orcid.org/0000-0002-8505-7430"]},"institutions":[{"id":"https://openalex.org/I4405264518","display_name":"Barts Cancer Institute","ror":"https://ror.org/0266wrt04","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079","https://openalex.org/I4405264518"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"John Gribben","raw_affiliation_strings":["Centre for Haemato-Oncology, Barts Cancer Institute, London, United Kingdom,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre for Haemato-Oncology, Barts Cancer Institute, London, United Kingdom,","institution_ids":["https://openalex.org/I4405264518"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5001047632","https://openalex.org/A5026718910","https://openalex.org/A5028402374","https://openalex.org/A5040118446","https://openalex.org/A5107969739","https://openalex.org/A5112467392"],"corresponding_institution_ids":["https://openalex.org/I17937529","https://openalex.org/I4405264518"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.4123,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.63657857,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"122","issue":"21","first_page":"4120","last_page":"4120"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9810000061988831,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9810000061988831,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.00989999994635582,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.005100000184029341,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.996999979019165},{"id":"https://openalex.org/keywords/t-cell-dysfunction","display_name":"T cell dysfunction","score":0.9639999866485596},{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.8809999823570251},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.9879999756813049},{"id":"https://openalex.org/keywords/pd-l2","display_name":"PD-L2","score":0.9980000257492065},{"id":"https://openalex.org/keywords/ibrutinib","display_name":"ibrutinib","score":0.9129999876022339},{"id":"https://openalex.org/keywords/immunological-synapse","display_name":"immunological synapse","score":0.7919999957084656},{"id":"https://openalex.org/keywords/t-cell-exhaustion","display_name":"T cell exhaustion","score":0.8149999976158142},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.6729999780654907},{"id":"https://openalex.org/keywords/adoptive-transfer","display_name":"adoptive transfer","score":0.6290000081062317},{"id":"https://openalex.org/keywords/emu-tcl1-mouse-model","display_name":"E\u03bc-TCL1 mouse model","score":0.8169999718666077},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.5809999704360962},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.5180000066757202},{"id":"https://openalex.org/keywords/b-cell-receptor-signaling","display_name":"B cell receptor signaling","score":0.5630000233650208},{"id":"https://openalex.org/keywords/chronic-antigen-stimulation","display_name":"chronic antigenic stimulation","score":0.6420000195503235},{"id":"https://openalex.org/keywords/spleen","display_name":"spleen","score":0.39500001072883606},{"id":"https://openalex.org/keywords/adoptive-t-cell-therapy","display_name":"adoptive T cell therapy","score":0.5149999856948853}],"concepts":[{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.6309274435043335},{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.6305058598518372},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.5550308227539062},{"id":"https://openalex.org/C2779343474","wikidata":"https://www.wikidata.org/wiki/Q3109175","display_name":"Context (archaeology)","level":2,"score":0.504149317741394},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.502479076385498},{"id":"https://openalex.org/C2781053074","wikidata":"https://www.wikidata.org/wiki/Q21100639","display_name":"PD-L1","level":4,"score":0.5012979507446289},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.48215028643608093},{"id":"https://openalex.org/C9756297","wikidata":"https://www.wikidata.org/wiki/Q126223","display_name":"Immunological synapse","level":5,"score":0.47521668672561646},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4560430645942688},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.4159667491912842},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.36745381355285645},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3590952455997467},{"id":"https://openalex.org/C19317047","wikidata":"https://www.wikidata.org/wiki/Q412037","display_name":"T-cell receptor","level":4,"score":0.2811225950717926},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.27784329652786255},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.21149462461471558},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.12696951627731323},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.07043194770812988},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v122.21.4120.4120","doi":"https://doi.org/10.1182/blood.v122.21.4120.4120","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.4120.4120","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4389247105","https://openalex.org/W2964765132","https://openalex.org/W4234891706","https://openalex.org/W2979764934","https://openalex.org/W2914382765","https://openalex.org/W3010073081","https://openalex.org/W7015503559","https://openalex.org/W2734526350","https://openalex.org/W4292332436","https://openalex.org/W866470737"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"CLL-induced":[2],"severe":[3],"T-cell":[4,30,68,195,198,216,243,336,345,508,616,626,659],"dysfunction":[5,31,617,660],"and":[6,35,83,112,125,128,173,178,201,210,240,248,259,276,320,342,344,354,361,383,412,433,496,504,551,555,558,583,599,614,624,631],"ineffective":[7],"anti-tumor":[8],"immune-responses":[9],"are":[10,180,204,618,628],"hallmarks":[11],"of":[12,29,79,97,114,119,122,135,145,147,157,168,187,238,242,271,282,316,339,417,455,479,502,588,648,656],"the":[13,16,66,95,131,151,184,232,235,497,536,604,645],"disease,":[14],"but":[15,420,528,594,621],"specific":[17],"interactions":[18,129,137],"remain":[19],"poorly":[20],"understood.":[21],"The":[22],"PD-1/PD-L1":[23,136],"axis":[24],"is":[25,72,190,234,398,464,475,651],"an":[26,141],"important":[27],"mediator":[28,655],"in":[32,94,110,193,214,245,300,363,409,510,519,608,661],"solid":[33],"tumors,":[34],"we":[36,227,467],"have":[37,62,87,228],"previously":[38,229],"demonstrated":[39,103,230],"that":[40,65,84,104,164,231,388,472,612,622,644],"T":[41,85,91,176,351,357,396,581,592],"cells":[42,86,92,172,177,274,286,358,371,397,419,440,546,582],"from":[43,256],"CLL":[44,59,171,179,266,273,318,418,438,456,480,613],"patients":[45],"exhibit":[46],"impaired":[47,518,549,553,562],"immunological":[48],"synapse":[49],"(IS)":[50],"formation,":[51],"predominantly":[52],"mediated":[53],"by":[54,221,310,400,415,638],"PD-L1":[55,169,341,432],"(CD274)":[56],"expression":[57,167,209,338,404,436,474,576],"on":[58,170,175,254,277,392,437,487,577],"cells.":[60,374,448,490,570],"We":[61,491,641],"also":[63,73,191,406,642,652],"shown":[64],"corresponding":[67],"ligand":[69,186,647],"PD-1":[70,174,208,212,390,403,575,657],"(CD279)":[71],"upregulated,":[74],"probably":[75],"as":[76,372],"a":[77,326,426,459,476,559,653],"result":[78],"chronic":[80,98],"antigenic":[81],"stimulation,":[82],"similarities":[88],"to":[89,162,207,294,334,445,470,499,526,531,535,564,568,596,603],"exhausted":[90],"observed":[93],"context":[96],"viral":[99],"infection.":[100],"Recent":[101],"studies":[102,378],"ibrutinib":[105,299,573,639],"has":[106],"impressive":[107],"clinical":[108],"activity":[109],"CLL,":[111,158],"mechanisms":[113],"action":[115,146],"include":[116],"irreversible":[117],"binding":[118],"essential":[120],"components":[121],"both":[123,524],"B-cell-":[124],"T-cell-receptor":[126],"signaling":[127],"with":[130,223,264,296,367,429,482,512,572],"tumor":[132],"microenvironment.":[133],"Modulation":[134],"might":[138,632],"therefore":[139],"be":[140,219,407,633],"additional":[142,289],"potential":[143],"mode":[144],"this":[148],"drug.":[149],"Using":[150,449],"well-established":[152],"E\u03bc-TCL1":[153],"(TCL1)":[154],"mouse":[155,284],"model":[156],"our":[159],"aims":[160],"were":[161,252,292,359,441,468,523],"demonstrate":[163],"(1)":[165],"altered":[166],"causally":[181,619],"related,":[182,620],"(2)":[183],"second":[185,646],"PD-1,":[188,340,649],"PD-L2,":[189,650],"involved":[192],"mediating":[194],"dysfunction,":[196],"(3)":[197],"effector":[199,346,494],"function":[200,495],"IS":[202,364,501,566],"formation":[203,365],"directly":[205],"linked":[206],"(4)":[211],"associated":[213,658],"vivo":[215,609],"responses":[217],"can":[218],"modulated":[220],"treatment":[222,295],"ibrutinib.":[224],"Methods":[225],"As":[226],"spleen":[233],"major":[236],"organ":[237],"disease":[239],"representative":[241],"changes":[244,627],"peripheral":[246],"blood":[247],"lymph":[249],"nodes,":[250],"experiments":[251],"performed":[253],"spleens":[255],"young":[257,410],"TCL1":[258,381,411,450],"wild-type":[260],"(WT)":[261],"C57Bl/6":[262],"mice":[263,291,382,414,451,511],"established":[265],"after":[267,280,314],"adoptive":[268],"transfer":[269],"(AT)":[270],"syngeneic":[272,317],"(n=10),":[275],"matched":[278],"litter-mates":[279],"AT":[281,315,416],"healthy":[283,368,422,446,460,488],"B":[285,370,423,439,447,489,534,601],"(n=10).":[287],"An":[288],"12":[290],"randomized":[293],"25":[297],"mg/kg/d":[298],"10%":[301],"HP-\u03b2-CD,":[302],"vehicle":[303],"control,":[304],"or":[305],"sterile":[306],"water,":[307],"all":[308],"administered":[309],"gavage,":[311],"three":[312],"weeks":[313],"cells,":[319,352,424,481,593],"sacrificed":[321],"20":[322],"days":[323],"later":[324],"at":[325,452,634],"pre-defined":[327],"endpoint.":[328],"Multicolor":[329],"flow":[330],"cytometry":[331],"was":[332,516],"used":[333,362],"characterize":[335],"subsets,":[337,521],"PD-L2":[343,434,473,483],"function.":[347],"Entire":[348],"population":[349,463,590],"CD8":[350,356,395,580,591],"PD-1+ve":[353,503,545],"PD-1-ve":[355,505,569],"flow-sorted":[360],"assays":[366],"murine":[369],"antigen-presenting":[373],"Results":[375],"Our":[376,607],"previous":[377],"using":[379],"aged":[380],"age-matched":[384],"WT":[385,413],"controls":[386],"indicated":[387],"CLL-related":[389],"upregulation":[391],"antigen-experienced":[393,506,578],"CD44+":[394,507,579],"masked":[399],"aging.":[401],"However,":[402],"could":[405],"induced":[408],"not":[421,629],"suggesting":[425],"causal":[427],"relationship":[428],"disease.":[430],"Both":[431],"surface":[435],"significantly":[442,548],"increased":[443],"compared":[444,493,567],"early":[453],"stages":[454],"development":[457],"when":[458],"CD19+":[461],"B-cell":[462],"still":[465],"present,":[466],"able":[469,525],"confirm":[471],"unique":[477],"feature":[478],"being":[484],"virtually":[485],"absent":[486],"next":[492],"ability":[498,563],"form":[500,565],"subsets":[509,539],"CLL.":[513,662],"While":[514],"proliferation":[515,598],"equally":[517],"these":[520],"they":[522],"degranulate":[527],"generally":[529],"failed":[530,595],"localize":[532],"granzyme":[533,600],"IS.":[537,605],"Although":[538],"produced":[540],"some":[541],"IL2/TNF\u03b1/IFN\u03b3":[542],"cytokine":[543],"responses,":[544],"had":[547],"TNF\u03b1":[550],"slightly":[552],"IL2":[554],"IFN\u03b3":[556,586],"production,":[557],"highly":[560],"significant":[561],"Treatment":[571],"reduced":[574],"promoted":[584],"stronger":[585],"production":[587],"entire":[589],"restore":[597],"relocation":[602],"Conclusion":[606],"data":[610],"suggests":[611],"PD-1/PD-L1-mediated":[615],"phenotypic":[623],"functional":[625],"absolute":[630],"least":[635],"partly":[636],"reversible":[637],"treatment.":[640],"show":[643],"critical":[654],"Disclosures:":[663],"Riches:":[664],"Celgene:":[665],"Research":[666,669],"Funding.":[667],"Gribben:Celgene:":[668],"Funding;":[670],"Pharmacyclics:":[671],"Honoraria;":[672],"Roche:":[673],"Honoraria.":[674]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2015,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}